State IA
Clinical Trials in Iowa
Iowa is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Iowa and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.
Right now ClinicalMetric tracks 107 actively recruiting studies with Iowa sites out of 107 registered in total. The busiest research areas in Iowa are Breast Cancer, Metastatic Breast Cancer, Stage IVB Prostate Cancer AJCC v8. Leading sponsors running trials in the state include National Cancer Institute (NCI), AstraZeneca, Alliance for Clinical Trials in Oncology. By stage, Iowa trials break down as Phase 1 (14), Phase 2 (29), Phase 3 (36), Phase 4 (4).
All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.
Top Conditions in Iowa
Breast Cancer (4)Metastatic Breast Cancer (3)Stage IVB Prostate Cancer AJCC v8 (2)Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 (2)Locally Recurrent Head and Neck Squamous Cell Carcinoma (2)Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma (2)Locally Recurrent Laryngeal Squamous Cell Carcinoma (2)Locally Recurrent Oral Cavity Squamous Cell Carcinoma (2)Locally Recurrent Oropharyngeal Squamous Cell Carcinoma (2)Stage III Laryngeal Cancer AJCC v8 (2)Stage III Lip and Oral Cavity Cancer AJCC v8 (2)Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 (2)
Frequently Asked Questions — Clinical Trials in Iowa
How many clinical trials are currently recruiting in Iowa?
ClinicalMetric currently tracks 107 actively recruiting clinical trials with at least one location in Iowa. The total number of registered studies—including active but not currently enrolling trials—is 107. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Iowa?
Iowa hosts clinical trials across a broad range of medical conditions, including Breast Cancer, Metastatic Breast Cancer, Stage IVB Prostate Cancer AJCC v8, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Iowa serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Iowa?
To join a clinical trial in Iowa, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Iowa maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.
Recruiting Trials in Iowa
NCT06215716 Phase 3
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Stea...
Condition
NASH With Fibrosis
Enrollment
1,650 pts
Location
United States, Argentina, Australia
Sponsor
Akero Therapeutics, Inc
NCT00358943 N/A
Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Preg...
Condition
Gaucher Disease
Enrollment
12,000 pts
Location
United States, Argentina, Australia
Sponsor
Genzyme, a Sanofi Company
NCT05918861 Phase 3
Recruiting
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Rece...
Condition
Acute Coronary Syndrome
Enrollment
2,000 pts
Location
United States, Canada, Puerto Rico
Sponsor
DalCor Pharmaceuticals
NCT04064359 Phase 1
Recruiting
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid T...
Condition
Solid Tumor
Enrollment
200 pts
Location
United States, Belgium, France
Sponsor
Oxford BioTherapeutics Ltd
NCT06316297 Phase 1, Phase 2
Recruiting
Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Ad...
Condition
Acne
Enrollment
800 pts
Location
United States, Australia, Canada
Sponsor
Sanofi Pasteur, a Sanofi Compa
NCT04402788 Phase 2, Phase 3
Recruiting
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment ...
Condition
Extensive Stage Lung Small Cell Carcinoma
Enrollment
138 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT07266441 Phase 2
Recruiting
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Mye...
Condition
Multiple Myeloma
Enrollment
157 pts
Location
United States, China, Israel
Sponsor
Janssen Research & Development
NCT04322318 Phase 2
Recruiting
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and R...
Condition
Anaplastic Kidney Wilms Tumor
Enrollment
256 pts
Location
United States, Australia, Canada
Sponsor
Children's Oncology Group
NCT06182397 N/A
Recruiting
Sirolimus Coated BALloon Versus Standard Balloon Angioplasty in The Treatment of...
Condition
Arterial Disease of Legs
Enrollment
368 pts
Location
United States
Sponsor
Concept Medical Inc.
NCT03808922 Phase 3
Recruiting
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substu...
Condition
Lower Respiratory Tract Infection
Enrollment
274 pts
Location
United States, Australia, China
Sponsor
Ansun Biopharma, Inc.
NCT00231400 N/A
Recruiting
Pompe Disease Registry Protocol
Condition
Glycogen Storage Disease Type II
Enrollment
2,000 pts
Location
United States, Argentina, Australia
Sponsor
Genzyme, a Sanofi Company
NCT05429632 Phase 3
Recruiting
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Al...
Condition
Adult Acute Myeloid Leukemia
Enrollment
366 pts
Location
United States, Argentina, Brazil
Sponsor
Priothera SAS
NCT04804644 Phase 3
Recruiting
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Who...
Condition
Metastatic Lung Small Cell Carcinoma
Enrollment
200 pts
Location
United States, Canada
Sponsor
NRG Oncology
NCT06330493 N/A
Recruiting
AcoArt Litos PCB Below-the-knee Global Trial
Condition
Chronic Limb-Threatening Ischemia
Enrollment
288 pts
Location
United States, Austria, Belgium
Sponsor
Acotec Scientific Co., Ltd
NCT06997497 Phase 3
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy ...
Condition
Colon Adenocarcinoma
Enrollment
477 pts
Location
United States, Argentina, Australia
Sponsor
Merck Sharp & Dohme LLC
NCT05318417 N/A
Recruiting
Investigation to Evaluate the Safety and Effectiveness of Cochlear Implantation ...
Condition
Hearing Loss, Unilateral
Enrollment
60 pts
Location
United States
Sponsor
Cochlear
NCT06084806 Phase 2
Recruiting
Test-retest Evaluation of [18F]F-AraG PET
Condition
Non-small Cell Lung Cancer
Enrollment
10 pts
Location
United States
Sponsor
CellSight Technologies, Inc.
NCT06739122 Phase 3
Recruiting
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants W...
Condition
Type 2 Diabetes
Enrollment
55 pts
Location
United States, Argentina, Mexico
Sponsor
Eli Lilly and Company
NCT06422923 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral...
Condition
Epilepsy, Temporal Lobe
Enrollment
10 pts
Location
United States
Sponsor
Neurona Therapeutics
NCT04543461 N/A
Recruiting
American Lung Association (ALA) Lung Health Cohort
Condition
Lung Diseases
Enrollment
4,000 pts
Location
United States
Sponsor
Johns Hopkins University
NCT07321886 Phase 3
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight ...
Condition
Obesity
Enrollment
1,980 pts
Location
United States, Argentina, Australia
Sponsor
Eli Lilly and Company
NCT06165341 Phase 3
Recruiting
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alp...
Condition
Alpha1-Antitrypsin Deficiency
Enrollment
50 pts
Location
United States, Austria, Belgium
Sponsor
Takeda
NCT06587529 N/A
Recruiting
Rigorous Evaluation of the READY to Stand Curriculum to Prevent the Commercial S...
Condition
Sex Trafficking
Enrollment
3,218 pts
Location
United States
Sponsor
University of Michigan
NCT06058377 Phase 3
Recruiting
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy T...
Condition
Anatomic Stage II Breast Cancer AJCC v8
Enrollment
3,680 pts
Location
United States, Puerto Rico
Sponsor
National Cancer Institute (NCI
NCT03257033 Phase 3
Recruiting
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radio...
Condition
Locally Advanced Pancreatic Cancer
Enrollment
190 pts
Location
United States, Belgium
Sponsor
RenovoRx
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology